BiotechTube
Home/Orgenesis/Heiko von der Leyen
HV

Heiko von der Leyen

Medical Director

Orgenesis

Therapeutic Areas

Immuno-OncologyViral DiseasesMetabolic & Autoimmune DiseasesVascular & Musculoskeletal DiseasesKidney Disease

Orgenesis Pipeline

DrugIndicationPhase
ORGCAR19 (CD19 CAR-T)B-ALL, LymphomaClinical Trials
MOTC (Metabolic Optimized T-Cells)Lung Cancer; MelanomaResearch
DUVAC (Cellular vaccine)Solid Tumors; Pancreatic CancerResearch
ORGCAR19.22 (CD19.22 CAR-T)B-ALLResearch
CAR-NKMultiple Myeloma, Ovarian CancerResearch
RanTopHPV: Genital Warts; Anal DysplasiaPhase 2b
SVF-COVCovid-19 Related ARDSPhase 2b
AutoVacCovid-19 VaccineResearch

Leadership Team at Orgenesis

VC
Vered Caplan
President, Chief Executive Officer and Director
NR
Neil Reithinger
Chief Financial Officer
EF
Evan Fishman
Chief Financial Officer of Orgenesis Biotech
VM
Victor Miller
Chief Financial Officer of Orgenesis
SH
Shimon Hassin
Chief Technology Officer
DS
Dan Slonim
Chief Operating Officer, General Manager of Orgenesis Israel
EA
Efrat Assa Kunik
Chief Development Officer
FT
Frederic Tonglet
General Manager of Orgenesis Belgium
PM
Peter Molloy
Executive Vice President, Corporate Development
JG
Joseph Green
Chief Operating Officer
View full Orgenesis profile